We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
Journal of Clinical Gastroenterology 2016 January
Biological drugs have significantly improved the quality of life of patients with inflammatory bowel disease. However, after 15 years of using these drugs in practice, we just now are beginning to better understand how to use them most effectively. It has become evident that antitumor necrosis factor agents, such as infliximab, have variable drug clearance across individuals, mostly related to the disease burden at the time of an infusion. In this case report, we demonstrate how therapeutic drug monitoring can be used to personalize a dosing regimen to ensure appropriate induction, and to safely deescalate therapy after remission is achieved. By identifying a change in drug clearance in an individual patient over time, we were able to attain significant cost savings despite the high price of serially measured drug and antibody concentrations.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app